回盛生物(300871) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥205,665,754.61, a decrease of 34.40% compared to ¥313,499,906.84 in the same period last year[5] - Net profit attributable to shareholders was ¥2,023,854.94, down 96.81% from ¥63,457,333.99 year-on-year[5] - Basic earnings per share dropped to ¥0.01, a decline of 97.37% from ¥0.38 in the previous year[6] - Total operating revenue for Q1 2022 was CNY 205,665,754.61, a decrease of 34.4% compared to CNY 313,499,906.84 in Q1 2021[28] - Gross profit for Q1 2022 was CNY 4,179,499.36, significantly lower than CNY 73,631,806.44 in Q1 2021, indicating a decline of 94.3%[30] - Net profit for Q1 2022 was CNY 2,023,854.94, a decrease of 96.8% compared to CNY 63,457,333.99 in Q1 2021[30] - Basic earnings per share for Q1 2022 were CNY 0.01, down from CNY 0.38 in Q1 2021[31] Cash Flow - The net cash flow from operating activities was -¥16,025,127.81, an improvement of 20.12% compared to -¥20,061,570.80 in the same period last year[6] - Total cash inflow from operating activities was 223,182,661.77, down from 305,652,169.46 in the previous period, indicating a decrease of approximately 27%[34] - Cash outflow from operating activities totaled 239,207,789.58, compared to 325,713,740.26 in the previous period, reflecting a decrease of about 26.5%[34] - The net cash flow from investing activities was -¥376,449,232.15, a decline of 347.08% compared to ¥152,360,259.27 in the previous year[15] - Cash inflow from investing activities was 30,353,258.20, down from 411,485,219.59 in the previous period, representing a decrease of approximately 92.6%[35] - Cash outflow from investing activities increased to 406,802,490.35, compared to 259,124,960.32 in the previous period, marking an increase of about 56.9%[35] - Cash inflow from financing activities was 70,000,000.00, up from 20,000,000.00 in the previous period, indicating a growth of 250%[35] - The net cash flow from financing activities was 1,375,366.95, compared to -18,216,687.38 in the previous period, showing a turnaround[35] - The ending cash and cash equivalents balance was 575,070,614.85, compared to 399,596,815.86 in the previous period, reflecting an increase of approximately 44%[35] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,701,491,465.45, a decrease of 1.47% from ¥2,741,662,030.01 at the end of the previous year[6] - Total liabilities for Q1 2022 were CNY 1,135,079,667.38, compared to CNY 1,122,808,244.46 in Q1 2021, showing a slight increase of 1.1%[27] - Current assets decreased to CNY 1,431,758,454.96 from CNY 1,598,881,606.08, a decline of 10.5% year-over-year[26] - Non-current assets increased to CNY 1,269,733,010.49 from CNY 1,142,780,423.93, reflecting an increase of 11.1%[27] - The company’s total liabilities increased by 40.00% in short-term borrowings, amounting to ¥140,000,000.00, due to increased borrowing during the reporting period[12] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,594[17] - The largest shareholder, Wuhan Tongsheng Investment Co., Ltd., holds 49.80% of shares, amounting to 82,800,000 shares, with 7,500,000 shares pledged[18] - The top ten shareholders include several investment firms, indicating a diverse ownership structure[19] - The company reported cash dividends of RMB 3.31 per 10 shares, totaling RMB 55,028,262.43 distributed to shareholders[22] Research and Development - Research and development expenses increased by 64.91% to ¥9,754,406.16, reflecting the company's commitment to enhancing R&D efforts[14] - The company reported a significant increase in research and development expenses, which rose to CNY 9,754,406.16 from CNY 5,914,988.69, marking a growth of 64.1%[29] Performance Goals - The company adjusted its performance assessment indicators for the 2021 restricted stock incentive plan, requiring a net profit growth rate of no less than 30% for 2021[20] - The company plans to achieve a revenue or net profit growth of no less than 65% for 2022, based on 2020 figures[20] Other Information - The company experienced a 1124.09% increase in non-operating expenses, totaling ¥2,010,149.96, primarily due to increased donations for university collaborations[14] - The company has initiated the repurchase and cancellation of 195,200 shares from the 2021 incentive plan[21] - As of March 31, 2022, cash and cash equivalents decreased to RMB 682,339,687.30 from RMB 1,068,233,710.99 at the beginning of the year, a decline of approximately 36.2%[24] - Accounts receivable increased to RMB 249,964,032.82 from RMB 231,856,552.45, reflecting a growth of about 7.8%[24] - Inventory decreased to RMB 201,968,517.77 from RMB 231,550,585.15, a reduction of approximately 12.7%[24] - The company’s first quarter report was not audited[36]